Related Experiment Video
Updated: Aug 11, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
[Interdigitating dendritic cell sarcoma-a case report with literature review]
Wen-Jin Gao1, Ri Zhang, Hong-Xia Qiu
1Jiangsu Institute of Hematology, First Affiliated Hospital, Suzhou University, Suzhou 215006, China.
Insights
Interdigitating dendritic cell sarcoma (IDCS) is a rare cancer with no distinct features. Diagnosis requires specialized tests, and while chemotherapy shows variable results, the tumor remains aggressive.
Area of Science:
- Oncology
- Pathology
- Hematology
Background:
- Interdigitating dendritic cell sarcoma (IDCS) is a rare malignant neoplasm of dendritic cells.
- Accurate diagnosis is challenging due to the lack of specific clinical and histopathological features.
Observation:
- A case of IDCS in a 41-year-old male presenting with left neck lymphadenopathy is reported.
- Peripheral blood and bone marrow examinations revealed abnormalities.
- Diagnosis was confirmed using immunohistochemistry and electron microscopy.
Findings:
- IDCS lacks distinctive clinical or pathohistological characteristics, necessitating advanced diagnostic techniques.
- Immunohistochemistry and electron microscopy are critical for differentiating IDCS from other histiocytic/dendritic cell neoplasms.
- The patient received ABVD chemotherapy, achieving partial response but failing to control tumor infiltration, indicating aggressive tumor behavior.
Implications:
- This case highlights the diagnostic challenges associated with IDCS.
- Early and accurate diagnosis using specialized techniques is crucial for appropriate management.
- The variable response to chemotherapy underscores the aggressive nature of IDCS and the need for further research into effective treatment strategies.
Objective:
To report a case of interdigitating dendritic cell sarcoma (IDCS).
Patient Material:
The patient was a 41-year-old man with a lymph node bulging in the left neck. Laboratory examination of peripheral blood and bone marrow was abnormal. The diagnosis of IDCS was made by immunohistochemistry and electron microscopy. Treatment of this patient with ABVD regimen (adriamycin, bleomycin, vinblastine, dacarbazine) resulted in obvious improvement, but did not control the tumor infiltration.
Conclusion:
IDCS has no distinctive clinical or pathohistological characteristics. Immunohistochemistry and electron microscopy are crucial in distinguishing it from other histiocytic/dendritic cell neoplasms. IDCS displays an aggressive behaviour, and the responses to chemotherapy are variable.
